← Back
Prime Medicine
PRME · listed on Nasdaq · worth $828.8 million
$3.67
+20.50% today
No insider bought or sold Prime Medicine stock on the market in the last year.
◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
115.0M shares
64% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
No insider bought or sold Prime Medicine stock on the market in the last year. The reports below are share awards and other paperwork.
All reports
Every insider trade and SEC report we hold for Prime Medicine.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 5, 2025BoughtGV 2021 GPAug 5, 2025 · Traded Aug 1, 2025 · 10% owner+46%via a trust or family1,500,000 @ $3.30$4.95M
Aug 1, 2025BoughtARCH Venture Partners XIIAug 1, 2025 · 10% owner+49%via a trust or family3,030,300 @ $3.30$10M
Aug 1, 2025BoughtARCH Venture Partners XAug 1, 2025 · 10% owner+49%via a trust or family3,030,300 @ $3.30$10M
3 more with Pro →Analysts, earnings and news
Analysts' price target
$7.11 average
11 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 4 quarters above
Q2 '26−$0.24 a share+$0.02
Q1 '26−$0.28 a share−$0.03
Q4 '25−$0.24 a share+$0.02
Q3 '25−$0.32 a share−$0.07